Cereno Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cereno ScientificDie Umsatzerlöse des Unternehmens werden voraussichtlich um 142.2% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 18.1% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 16.9% pro Jahr wachsen.

Wichtige Informationen

12.9%

Wachstumsrate der Gewinne

16.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	39.5%
Wachstumsrate der Einnahmen	-162.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Sep 01

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Apr 05

Gewinn- und Umsatzwachstumsprognosen

OM:CRNO B - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-47	N/A	N/A	1
12/31/2024	N/A	-49	N/A	N/A	1
3/31/2024	55	-59	-102	-46	N/A
12/31/2023	49	-48	-86	-37	N/A
9/30/2023	53	-35	-83	-30	N/A
6/30/2023	58	-31	-93	-35	N/A
3/31/2023	65	-27	-86	-21	N/A
12/31/2022	58	-28	-76	-19	N/A
9/30/2022	52	-23	-74	-22	N/A
6/30/2022	51	-19	-79	-9	N/A
3/31/2022	49	-18	-64	-16	N/A
12/31/2021	45	-16	-58	-13	N/A
9/30/2021	31	-17	-44	-13	N/A
6/30/2021	23	-17	-15	-12	N/A
3/31/2021	9	-16	-23	-14	N/A
12/31/2020	8	-16	-24	-16	N/A
9/30/2020	0	0	7	6	N/A
6/30/2020	-1	0	7	6	N/A
3/31/2020	0	1	-3	-3	N/A
12/31/2019	0	-1	-1	-1	N/A
9/30/2019	10	-16	-32	-22	N/A
6/30/2019	10	-16	-32	-20	N/A
3/31/2019	9	-15	-19	-9	N/A
12/31/2018	7	-12	-17	-9	N/A
9/30/2018	6	-9	-15	-7	N/A
6/30/2018	9	-8	-16	-7	N/A
3/31/2018	9	-6	-16	-5	N/A
12/31/2017	9	-5	N/A	-4	N/A
9/30/2017	9	-4	N/A	-3	N/A
6/30/2017	6	-4	N/A	-5	N/A
3/31/2017	6	-6	N/A	-6	N/A
12/31/2016	5	-6	N/A	-5	N/A
9/30/2016	3	-5	N/A	-7	N/A
6/30/2016	3	-4	N/A	-4	N/A
3/31/2016	1	-1	N/A	-1	N/A
12/31/2015	1	0	N/A	-1	N/A
8/31/2015	0	0	N/A	0	N/A
8/31/2014	1	0	N/A	0	N/A
8/31/2013	0	0	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRNO B wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CRNO B wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CRNO B wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CRNO B wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CRNO B wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRNO B in 3 Jahren voraussichtlich hoch sein wird

Cereno Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

New major risk - Financial position

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Director exercised options to buy kr1.0m worth of stock.

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

New major risk - Financial position

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Chief Medical Officer recently bought kr208k worth of stock

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought kr804k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr0.069 loss per share (vs kr0.047 loss in 3Q 2021)

No independent directors

Cereno Scientific's Patent Protection for Drug Candidate CS1 Expands in Mexico Through Its Second Patent Family

Cereno Scientific Reports First Patient Dosed in Phase II Study in PAH with Drug Candidate CS1

Second quarter 2022 earnings released

Cereno Scientific's Innovative Phase II Study Design in PAH with CS1 is Accepted for Presentation at the CHEST Annual Meeting on Oct. 16-19 in Nashville, US

Cereno Scientific Announces Enrolling the First Patient in Its Phase II Clinical Study with Lead Drug Candidate Cs1 in Pulmonary Arterial Hypertension

Cereno Scientific Reports First Patient Enrolled in Phase II Study in PAH with Drug Candidate CS1

Frejs Revisorer AB Announces Board Appointments

Cereno Scientific AB Appoints Nick Oakes as Head of Preclinical Development

Cereno Scientific AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

First quarter 2022 earnings released

Cereno Scientific's Abstract on CS1's Innovative Phase II Study Design Accepted At Top Pulmonary Vascular Congress PVRI Held in June, 2022

Cereno Scientific to Present Candidate Drug CS585 Preclinical Data At EHA 2022 - the Premier Medical Congress for Hematology

Cereno Scientific Nominates Drug Candidate CS585 in PCA Program for Continued Development in Cardiovascular Disease

No independent directors

Full year 2021 earnings released: kr0.15 loss per share (vs kr0.22 loss in FY 2020)

Cereno Scientific Appoints Fredrik Frick as Head of Clinical Operations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Cereno Scientific AB (publ) to Report Fiscal Year 2021 Final Results on Apr 06, 2022